– USA, NY – Algorithm Sciences, Inc. today announced the appointments of Anthony Zook and Gary Gemignani to its Board of Directors. The company is in the portfolio of Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd.
“We are thrilled to attract the caliber of talent that Tony and Gary bring to Algorithm. We believe it is a testament to Algorithm’s asset quality, and viable path to helping patients with rare cardiovascular diseases.” said Executive Chairman, Matthew Duffy.
These appointments come on the heels of the recent management appointments where Michael Tilton was named CEO, David Cavalier was named COO and CFO, and Matthew Duffy was named Executive Chairman of the company.
About Anthony Zook
Anthony Zook previously served as President and CEO of the North American division of AstraZeneca, and President of Medimmune. He also served as EVP of global commercial operations of AstraZeneca Plc. Mr. Zook has served as a director of BioSig Technologies, Inc (Nasdaq: BSGM) since July 2020, and is currently Executive Chairman and a member of the Board of Voltron Therapeutics, Inc. and had previously served as a member of the Board of Directors of AltheRx, InHibikase, Rib-X Pharmaceuticals, the National Pharmaceutical Council, PhRMA, the Pennsylvania Division of the American Cancer Society, Frostburg State University.
About Gary Gemignani
Gary Gemignani is a 30+ year finance & management executive. He currently serves as EVP, CFO, of Acacia Pharma. Before that, he served as EVP, CFO of Synergy Pharmaceuticals Inc. where he successfully led the sale of this Nasdaq-listed company’s assets to Bausch Health, CEO and CFO of Biodel Inc., where he also successfully led Biodel’s reverse merger with Albireo Ltd He has served in senior and executive financial and operational roles with multiple public and private companies including, Gentium, Novartis, and Wyeth. Gary started his career at Arthur Andersen & Co.
About Algorithm Sciences
Algorithm Sciences is focused on optimizing treatment for rare cardiovascular diseases. It is a Laidlaw Venture Partners portfolio company.
About Laidlaw & Company
Laidlaw & Company is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private institutions, public institutions, and high net worth individual investors.
Laidlaw & Company (U.K.) Ltd., a broker-dealer registered with FINRA in the United States, clears on a fully disclosed basis through Stone X, a member of the Securities Investor Protection Corporation. Laidlaw & Company International Limited, an affiliate of Laidlaw & Company, is authorized by the Financial Conduct Authority in the United Kingdom.
Laidlaw Wealth Management and Laidlaw Private Equity, LLC are affiliates of Laidlaw & Company (UK) Ltd.
Laidlaw Venture Partners is a dba of Laidlaw Private Equity.
For more information: https://laidlawltd.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
